Sign Out
For Insulin Glargine no clinical data on exposed pregnancies are available. Animal studies do not indicate reproductive toxicity. The use of SANSULIN Log-G may be considered during pregnancy if necessary.
It is essential for patients with pre-existing or gestational diabetes to maintain good metabolic control throughout pregnancy. Insulin requirements may decrease during the first trimester and generally increase during the second and third trimesters. Immediately after delivery, Insulin requirements decline rapidly (increase risk of hypoglycaemia), careful monitoring of glucose control is essential. It is unknown whether Insulin Glargine is excreted in human milk. No metabolic effect of ingested Insulin Glargine on the breast-fed newborn Infant are anticipated since Insulin glargine as a peptide is digested into amino acids in the human gastrointestinal tract. Breast-feeding women may require adjustment in insulin dose and diet.
